Abstract. Langerhans cell histiocytosis (LCH) is a heterologous disease with a recognized disparity in incidence, affected sites and prognosis between adults and children. The recent identifica tionofBRAF V600E mutations in LCH prompted the investigation of the frequency of these mutations in adult and childhood disease with the involvement of single or multiple sitesinthepresentstudy.ThestudyanalysedtheBRAF V600E statusinacohortofadultLCHpatientsbyDNAsequencing, andperformedabroadermeta-analysisofBRAF V600E mutations in LCH in order to investigate any association with disease site and severity. Areviewoftheliteraturerevealedthat~47%of lesions from cases of adult disease (patient age, >18 years) were V600E-positivecomparedwith53%inthoseunder18years. When single and multiple site disease was compared, there wasaslightincreaseintheformer(61vs.51%,respectively). Agreaterdifferencewasobservedwhenhigh-andlow-risk organswerecompared;forexample,75%ofliverbiopsies(a high-riskorgan)werereportedtobearthemutationcompared with47%oflungbiopsies.IntheadultLCHpopulation,DNA sequencing identified mutations in 38% of 29 individuals, whichisslightlylowerthanthefigureidentifiedfromthemetaanalysis (in which a total of 132 individuals were sampled), althoughwethisvaluecouldnotbebrokendownbyclinical status. Thus, V600E status at presentation in itself is not predictive of tumour course, but a considerable proportion of LCH patients may respond to targeted V600E therapies.
Introduction
Langerhans cell histiocytosis (LCH) is a rare disorder affecting adults and children, characterised by an abnormal accumulationofepidermalLangerhans-likecellsinvarious sites (1) (2) (3) . The aetiology and pathogenesis of LCH remains to be established, but it is hypothesized to be a clonal disorder (4, 5) .AdiagnosisofLCHismadefollowingthe detection of lesional cluster of differentiation (CD)1a + Langerhans-like cells, whereas non-Langerhans histiocytoses, including Erdheim Chester disease, are CD1a -. LCH is a heterogeneous disease, affecting all ages and ethnicities, anddiseasemaytakeavarietyofcourses:Certaindisease cases may spontaneously remit, while other cases may lead tofatality.Riskfactorsincludethetimetodiagnosisandthe site of lesions (6) . AstudyfromtheHistiocyteSocietyrecognisedadisparity in the site, age of onset and incidence of LCH between adults and children (7) . The age of onset in children is between 1-3 years, whereas adult disease is more heterogeneous, with a higher incidence in young (18-30 years) and older adults (>70 years) (7) . The reported incidence of LCH ranges from 0.5-5.4 cases per million persons per year (8) (9) (10) , but these figuresarelargelyassociatedwithchildhooddisease.The incidenceofadultdiseaseislikelytobeunderreported,as LCH is frequently treated according to the affected system, without a secondary referral. Childhood disease is more likelytobereferredtoanoncologist,providingmoreaccurate statistics.
Although childhood LCH lesions tend to predominate in bone (11) , adult LCH is more widespread, commonly presenting in the skin, bone and lung. Table I lists the common sites of LCH in both adults and children reported in several previous studies (6, 7, 12) . This heterogeneity, coupled with relative scarcity, renders it challenging to implement randomized control trials in adults or children to optimize therapy. Notwithstanding the Histiocyte Society's LCH protocolthatprovidesatherapeuticframework,treatmentfor LCH is variable across centres (13) .
Despite an unknown aetiology, the misguided myeloid dendritic cell precursor model provides one underlying mechanism to explain the abnormal localization and accumulation of dendritic cells (14, 15) , and this is consistent with the treatment of LCH as a haematological disease (at least in paediatric cases). Haematopoietic forms of cancer occur as a consequence of arrest at a discrete stage of an ordered developmental pathway, frequently associated with distinct patterns of mutation. This is in contrast to primary and metastatic solid tumours, which tend to exhibit a higher level of heterogeneity at the genetic level (16) .Themostsignificantrecent advance in the understanding of LCH has been provided by studies describing the high incidence of BRAF V600E mutations in childhood disease (17) (18) (19) . This observation, along with the immature phenotype of LCH cells, is consistent with the discrete patterns of mutation and arrested developmentobservedinhaematopoietictypesofcancer.Inorder to further investigate whether this mutation demonstrated a discrete pattern in LCH, the current study aimed to investigate theBRAF V600E status in a broader range of LCH cases (with respect to age and site) in order to establish whether there is commonality in the aetiology of a disease with heterologous presentation.Inaddition,theassessmentofnumerousbiopsies from patients with LCH presenting at multiple sites may provide further evidence for a clonal origin of this disorder.
Materials and methods
Meta-analysis. PubMed(www.ncbi.nlm.nih.gov/pubmed) was searched for manuscripts referencing LCH biopsies that had beensubjecttoBRAF V600E screening by direct sequencing, reverse transcription-polymerase chain reaction (PCR) or immunohistochemistry. Relevant patient information (disease classification and BRAF status) from 10 published manuscripts were isolated for meta-analysis (TableII) (15, (17) (18) (19) (20) (21) (22) (23) (24) (25) . Thesearchcriteriausedwere'BRAFV600E'and'Langerhans cellhistiocytosis'.Resultswerefilteredforadults(>18years) and paediatric disease (<18 years), and secondly according to diseasesite,includingboneorskin.
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V60 0E sequencing. Research Ethics Committee (REC) approval at Hammersmith Hospital (London, UK) was obtained for the present study (REC reference no. 60/Q0406/107).Intotal,33adultLCHsamples,representing 30patientswereavailabletoscreenfortheBRAF V600E mutation.DNAwasextractedfrom21archivalparaffinembedded LCH biopsies and 12 fresh biopsies enriched for CD1a positivecellsusinganAllPrepDNA/RNAFFPEkitandAllPrep DNA/RNAMinikitfromQiagen,Inc.(Valencia,CA,USA), respectively. The extractions were performed according to the manufacturer's protocol. CD1a-positive cell selection was performed using MACS CD1a MicroBeads kit purchased from Miltenyi Biotec, Inc. (Cambridge, MA, USA). Cells were selcted using magnetic beads coated with a human anti-mouseIgGmonoclonalantibodyandamagneticparticle concentrator according to the manufacturer's instructions. DNAqualitywasassessedusingaNanoDrop(ThermoFisher Scientific, Inc., Waltham, MA, USA). Amplification and sequencingofexon15oftheBRAFgenewasperformedby SourceBioScience(Nottingham,UK).SourceBioScience designedtheprimerpairsandperformedregion-specificPCR optimization,amplificationandsequencing.Theoligonucleotidesequenceswereasfollows:PCRforwardprimer(5' AAC ACA TTT CAA GCC CCA AA);PCRreverseprimer(5'AGC ATC TCA GGG CCA AAA AT); forward sequencing primer (5'TCA TAA TGC TTG CTC TGA TAG GA);reversesequencing primer(5'GGC CAA AAA TTT AAT CAG TGG A).PCRreactionmixescontained25ngDNA(oranotemplatecontrol), 0.6µMofeachprimerandRocheHigh-Fidelitymastermixat a1Xfinalconcentrationwiththefollowingconditions:Initial denaturationat94˚Cfor279sec;followedby35cyclesof 94˚Cfor20sec,55˚Cfor15secand65˚Cfor30sec;followed byafinalelongationstepat65˚Cfor60sec.PCRproducts were cleaned up using Zymo ZR-96 clean and concentrator kit(ZymoResearchCorp,Irvine,CA,USA).Productswere sequencedasstandardusinganABI3730machine(Thermo FisherScientific,Inc.).
Statistical analysis. Statistical analysis was performed using Prismstatisticssoftware(version4;GraphPadSoftware,Inc., LaJolla,CA,USA).Analysiswasperformedusingχ 2 and Fisher'sexacttests.P<0.05wasconsideredtoindicateastatis-ticallysignificantdifference.
Results
A meta-analysis of existing LCH BRAF V600E studies was performed to invesitigate the heterogeneity of LCH at the genetic level. Fig.1Arevealsnodifferenceintheprevalence ofBRAF V600E mutations between adult and paediatric LCH. Similarly, when the incidence of the BRAF V600E mutation invariousclinicalclassificationsofLCHwasevaluated,no significantdifferenceswereidentifiedbetweenmulti-system (MS)-LCHandfocalorsinglesystem(SS)LCH (Fig.1B) .In addition, investigation of the mutation in varying sites revealed no consistent pattern (Fig.1C) . TheresultsofBRAF V600E sequencing in adult LCH cases are presented in TableIII. Of the 29 patients analysed, 11 patients exhibitedaBRAF V600E mutation,whichcorrespondsto38% of patients with LCH being BRAFV600E-positive for the mutation. There were 3 patients for whom multiple samples were analysed. Lesional gum and bone samples from patient 16exhibiteddifferentialstatuswithrespecttotheBRAF V600E mutation. However, follow up with PCR revealed the two TableI.MostcommonsitesofLangerhanscellhistiocytosisin children and adults with their frequency, where reported. Bates et al, V600E -positive (data not shown), suggesting a low level of mutated cells in the gum sample below the sensitivitythresholdofsequencing.ItisofnotethatPCRanalysis did not identify V600E mutations in any other biopsies identifiedaswild-typebysequencing.Atotalof3lungsampleswere availableforpatient28,allofwhichwereBRAF V600E -positive. There were two lymph node samples available for patient 20, ofwhichonewasBRAF V600E -positive.Itispossiblethatone of these lymph node samples was obtained from a node not involved in the lesion; however, the clinical history of these samples is not available.
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Discussion

TheBRAF
V600E mutant was present in the adult population in the current study at a slightly lower frequency than that indicatedbythemeta-analysis(38vs.47%,respectively),albeit withnodiscerniblepatternlinkingthemutationtolesional site(skinorbone)ordiseaseseverity(SSorMS-LCH).While the meta-analysis revealed a higher prevalence of mutations in high-riskorgans,BRAF V600E status by itself does not necessarily identify high-risk disease. The present findings are broadlycomparablewiththosereportedbyBerreset al (25) . ConsistencyinBRAF V600E mutation status in more than one lesion from the same individual (with the exception of one lymph node biopsy) is consistent with a clonal origin of the disease (4, 5) .Moreover,thefactthatdendriticcellsderivefrom circulating myeloid precursors, and that lesional Langerhans cells have an immature phenotype, suggests that LCH can be considered to be a haematological tumour (14, 19) .
Haematopoietic forms of cancer typically exhibit arrested cell development at a discrete stage of an ordered developmental pathway, frequently associated with distinct patternsofmutation.Inaddition,theincreasedprevalence ofBRAF V600E mutationsinhigherriskorgansincludingthe liver and spleen (Fig.1C) was concordant with results from Héritier et al (26) suggesting that the expression of this mutationinat-riskorgansincreasestheaggressivenessof LCH, particularly in younger patients. Clinically, LCH is currently treated as a haematological disease in paediatric cases.
BRAF mutations in haematological malignancy are relatively rare (27, 28) .TheBRAF V600E mutation has a high prevalenceininhairycellleukaemiaandhasbeensuggested tobethedisease-definingeventinthisdisorder (29) .Itis, however,rareinotherB-cellorassociatedlymphoproliferative disorders (28) and is notably absent from chronic and acute myeloid neoplasms (30, 31) .
BRAFmutation-targetingtherapy,includingtheBRAF inhibitors vemurafenib and dabrafenib, have demonstrated evidenceoftherapeuticactivityinseveralBRAF V600E -mutated cancer types, including hairy cell leukaemia (29, (32) (33) (34) . However, the results of the current study suggest that, prior to administeringBRAFtherapy,cliniciansmustbeawarethat the mutation characterizes a subset of LCH and administration of such therapies should be predicted upon genotyping. Furthermore, the resistance-profile of BRAF inhibitors in melanoma (35) must be considered to ensure LCH is treated and eliminated, rather than driving drug resistance and limiting future clinical options. ThepresentstudyhasdemonstratedthatBRAF V600E mutations are present within a sub-population of LCH patients. The haematologicaltumourprofileexhibitedbyLCHsuggeststhat certaintreatmentsthatarecurrentlyundertakeninpaediatric LCH cases and for other haematopoietic types of cancer may aidthetreatmentofLCH.Aninvestigationoftheeffective treatmentsforhairycellleukaemiamayoffermoretherapeutic options for this disease.
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